Sabra Healthcare REIT Inc (NASDAQ: SBRA) has seen a rise in its stock price by 0.89 in relation to its previous close of 14.61. However, the company has experienced a 5.89% gain in its stock price over the last five trading sessions. Business Wire reported 2024-04-24 that TUSTIN, Calif.–(BUSINESS WIRE)– #1Q24–Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that it will issue its 2024 first quarter earnings release on May 8, 2024, after the close of trading. A conference call with a simultaneous webcast to discuss the 2024 first quarter results will be held on Thursday, May 9 at 10:00 a.m. Pacific Time. The dial-in number for U.S. participants is 888-880-4448. For participants outside the U.S., the dial-in number is 646-960-0572. The conference ID number i.
Is It Worth Investing in Sabra Healthcare REIT Inc (NASDAQ: SBRA) Right Now?
Sabra Healthcare REIT Inc (NASDAQ: SBRA) has a higher price-to-earnings ratio of 252.40x compared to its average ratio. SBRA has 36-month beta value of 1.21. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 7 as “hold,” and 1 as “sell.”
The public float for SBRA is 227.80M, and currently, short sellers hold a 4.98% ratio of that float. The average trading volume of SBRA on May 08, 2024 was 2.05M shares.
SBRA’s Market Performance
The stock of Sabra Healthcare REIT Inc (SBRA) has seen a 5.89% increase in the past week, with a 2.79% rise in the past month, and a 13.65% gain in the past quarter. The volatility ratio for the week is 2.33%, and the volatility levels for the past 30 days are at 2.06% for SBRA. The simple moving average for the past 20 days is 6.28% for SBRA’s stock, with a 7.71% simple moving average for the past 200 days.
Analysts’ Opinion of SBRA
Many brokerage firms have already submitted their reports for SBRA stocks, with Deutsche Bank repeating the rating for SBRA by listing it as a “Buy.” The predicted price for SBRA in the upcoming period, according to Deutsche Bank is $21 based on the research report published on January 30, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see SBRA reach a price target of $16. The rating they have provided for SBRA stocks is “Market Perform” according to the report published on October 17th, 2023.
Wells Fargo gave a rating of “Equal Weight” to SBRA, setting the target price at $15 in the report published on October 16th of the previous year.
SBRA Trading at 4.64% from the 50-Day Moving Average
After a stumble in the market that brought SBRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.14% of loss for the given period.
Volatility was left at 2.06%, however, over the last 30 days, the volatility rate increased by 2.33%, as shares surge +3.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.74% upper at present.
During the last 5 trading sessions, SBRA rose by +5.89%, which changed the moving average for the period of 200-days by +12.26% in comparison to the 20-day moving average, which settled at $13.89. In addition, Sabra Healthcare REIT Inc saw 3.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SBRA starting from Costa Michael Lourenco, who purchase 1,947 shares at the price of $12.63 back on Sep 01 ’23. After this action, Costa Michael Lourenco now owns 183,218 shares of Sabra Healthcare REIT Inc, valued at $24,591 using the latest closing price.
Stock Fundamentals for SBRA
Current profitability levels for the company are sitting at:
- 0.5 for the present operating margin
- 0.63 for the gross margin
The net margin for Sabra Healthcare REIT Inc stands at 0.02. The total capital return value is set at 0.06. Equity return is now at value 0.47, with 0.25 for asset returns.
Based on Sabra Healthcare REIT Inc (SBRA), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.86. The interest coverage ratio of the stock is 2.54.
Currently, EBITDA for the company is 418.15 million with net debt to EBITDA at 5.71. When we switch over and look at the enterprise to sales, we see a ratio of 8.96. The receivables turnover for the company is 1.31for trailing twelve months and the total asset turnover is 0.12.
Conclusion
To put it simply, Sabra Healthcare REIT Inc (SBRA) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
